Only 10 of the more than 220 viruses known to infect humans now have clinically licensed antiviral drugs. While vaccine development is continuing, the SARS-CoV-2 outbreak has highlighted the crucial need for substances that can be promptly mobilized for the treatment of re-emerging or developing viral illnesses. We will address the classical and molecular methodologies utilized throughout the preclinical antiviral drug development process in this session.
(Almokattam mall, street 9, 2nd floor, Almokattam, Cairo, Egypt.)